DE69428272D1 - Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum - Google Patents

Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum

Info

Publication number
DE69428272D1
DE69428272D1 DE69428272T DE69428272T DE69428272D1 DE 69428272 D1 DE69428272 D1 DE 69428272D1 DE 69428272 T DE69428272 T DE 69428272T DE 69428272 T DE69428272 T DE 69428272T DE 69428272 D1 DE69428272 D1 DE 69428272D1
Authority
DE
Germany
Prior art keywords
inhibiting
growth
cell activation
antibodies
cd2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69428272T
Other languages
English (en)
Other versions
DE69428272T2 (de
Inventor
Herve Bazin
Dominique Latinne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Application granted granted Critical
Publication of DE69428272D1 publication Critical patent/DE69428272D1/de
Publication of DE69428272T2 publication Critical patent/DE69428272T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69428272T 1993-03-05 1994-03-04 Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum Expired - Lifetime DE69428272T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2700893A 1993-03-05 1993-03-05
US11903293A 1993-09-09 1993-09-09
PCT/IB1994/000043 WO1994020619A1 (en) 1993-03-05 1994-03-04 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T-CELL ACTIVATION AND PROLIFERATION

Publications (2)

Publication Number Publication Date
DE69428272D1 true DE69428272D1 (de) 2001-10-18
DE69428272T2 DE69428272T2 (de) 2002-06-27

Family

ID=26701922

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428272T Expired - Lifetime DE69428272T2 (de) 1993-03-05 1994-03-04 Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum

Country Status (10)

Country Link
EP (1) EP0687300B1 (de)
JP (2) JP3711143B2 (de)
AT (1) ATE205531T1 (de)
AU (1) AU686600B2 (de)
CA (1) CA2157500C (de)
DE (1) DE69428272T2 (de)
DK (1) DK0687300T3 (de)
ES (1) ES2164699T3 (de)
PT (1) PT687300E (de)
WO (1) WO1994020619A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE69637943D1 (de) * 1996-08-16 2009-07-09 Biotransplant Inc LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
DE69732789T2 (de) 1996-12-06 2005-08-11 Aventis Pharmaceuticals Inc. Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
JP4808841B2 (ja) * 1997-07-18 2011-11-02 バイオトランスプラント，インコーポレイテッド Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその使用法
JP2001523645A (ja) 1997-11-14 2001-11-27 ザ・ゼネラル・ホスピタル・コーポレイション 血液学的疾患の処置
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
KR101240206B1 (ko) 2010-10-05 2013-03-06 고려대학교 산학협력단 자연살상 세포-매개 면역반응 억제용 조성물
SG11202004192XA (en) * 2017-11-29 2020-06-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd2+ cells
JP2022530026A (ja) 2019-04-24 2022-06-27 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマトキシン抗体薬物複合体及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody

Also Published As

Publication number Publication date
JP3711143B2 (ja) 2005-10-26
EP0687300B1 (de) 2001-09-12
DE69428272T2 (de) 2002-06-27
EP0687300A1 (de) 1995-12-20
AU6218194A (en) 1994-09-26
CA2157500C (en) 2005-08-16
JP4195453B2 (ja) 2008-12-10
PT687300E (pt) 2002-03-28
DK0687300T3 (da) 2001-12-31
CA2157500A1 (en) 1994-09-15
WO1994020619A1 (en) 1994-09-15
JPH08507438A (ja) 1996-08-13
JP2005239725A (ja) 2005-09-08
ES2164699T3 (es) 2002-03-01
ATE205531T1 (de) 2001-09-15
AU686600B2 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
ATE395081T1 (de) Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum
DE69129990T2 (de) Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
DK0592521T3 (da) Marv-afledte humane mesenchymal-stamceller og monoklonale antistoffer specifikke for nævnte celler
ATE132197T1 (de) Monoklonale antikörper
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
DE68921979T2 (de) Antikörper für die antilymphozyten-antikörpertherapie.
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE520834T1 (de) PP14 oder Antikörper gegen PP14 enthaltende pharmazeutische Zusammensetzung zur Behandlung von Immunsystemstörungen.
ATE99333T1 (de) Immunogen und seine verwendung zur gewinnung von antikoerpern gegen haemoglobin a1c.
GB2233559A (en) Antibodies for use in antilymphocyte antibody therapy
GR1002381B (el) Ουσιες σχετιζομενες με συμπληρωματικα πεπτιδια των νεκρωτικων παραγοντων ογκων h του r55-υποδοχεα του νεκρωτικου παραγοντα ογκων.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition